3billion
Back to ListBack to List

Hypochondroplasia vs. Achondroplasia: What Distinguishes Them

Rare disease series | 26. 07. 27

Key summary

  • Same gene, different hotspot. Achondroplasia arises at FGFR3 c.1138 (p.Gly380Arg); hypochondroplasia most often at c.1620 (p.Asn540Lys). A c.1138-only assay cannot detect the latter.
  • Guidance is explicit on testing both, because the two presentations are easily confused.
  • And that still leaves a gap. Targeted analysis of the c.1620 pair identifies ~70–80% of cases; full FGFR3 sequencing 70–90%; in 10–30% no FGFR3 variant is found.
  • Different surveillance, not just milder. Foramen magnum stenosis, spinal stenosis, tibial bowing and obstructive apnea occur less often than in achondroplasia — while temporal lobe epilepsy is the concern that rises.

1. Two conditions, one gene, two hotspots

Achondroplasia has an unusually concentrated molecular basis: more than 99% of patients carry one of two changes at a single position, c.1138G>A or c.1138G>C, both producing p.Gly380Arg [9]. That concentration is what makes targeted testing so efficient — and what makes it a trap in the condition next to it.

The genetics, diagnosis and treatment of achondroplasia itself are
covered separately in [Achondroplasia in children: from the FGFR3 mutation to Voxzogo]

Hypochondroplasia is also caused by FGFR3, but the recurrent variants sit elsewhere: c.1620C>A and c.1620C>G, both encoding p.Asn540Lys [1]. The architecture is a mirror image — two substitutions at one nucleotide producing one amino acid change — but the nucleotide is a different one. An assay designed around c.1138 returns a clean negative in a patient who has hypochondroplasia: accurate for the question asked, misleading as an answer to the question the clinician had.

The achondroplasia and hypochondroplasia hotspots lie in different FGFR3 domains.

GeneReviews states the consequence directly. Because individuals with the classic achondroplasia variants and the classic hypochondroplasia variants may have very similar presentations and are easily confused, both pairs of variants should be tested when molecular testing is requested for hypochondroplasia [1].

2. A case in which hotspot testing delayed the diagnosis

In a published case report, a fetus showed shortened limbs below the 3rd percentile, an increased biparietal diameter above the 95th percentile, and a low nasal bridge on serial ultrasound. Given the relative frequency of achondroplasia, targeted testing for the FGFR3 c.1138 hotspot was performed in the third trimester. It was negative [2].

The child continued to show growth retardation, rhizomelic disproportionate short stature, an enlarged head and short hands. Whole exome sequencing at one year of age identified FGFR3 c.1620C>A, and the diagnosis was hypochondroplasia [2]. The authors’ conclusion is worth stating plainly: hotspot testing should not serve as the sole basis for a clinical diagnosis, and where clinical findings conflict with a negative targeted result, further analysis should follow promptly rather than be deferred [2].

Current guidance anticipates this. Hypochondroplasia is typically suspected only late in the third trimester, from short long bones and a larger head circumference; because prenatal imaging may not demonstrate all features, a broad multigene panel including FGFR3, or comprehensive genomic testing, can be considered on a fetal sample [1,3]. A normal third-trimester ultrasound is not sufficient to exclude the diagnosis [1].

3. Testing both hotspots helps — and still leaves a gap

Two implications follow.

Full-gene sequencing outperforms hotspot analysis, because pathogenic variants outside c.1620 are recognized — c.829A>G (p.Tyr278Cys), which resembles achondroplasia in the newborn period; c.1043C>G (p.Ser348Cys), described as a mild-achondroplasia / severe-hypochondroplasia phenotype; and the p.Lys650 series [1].

For 10–30% of patients the gene is not the answer at all [1]. Locus heterogeneity is considered possible, and the diagnostic criteria themselves remain contested: no single clinical or radiologic feature is unique to hypochondroplasia, expression of the established features is variable, and no consensus exists on how many are required [1].

There is a counterintuitive corollary. Patients with N540K generally have more severe manifestations than those without it [1] — so the hotspot-negative group is enriched for the mildest, hardest-to-recognize presentations. The patients a targeted assay misses are precisely the patients a clinician is least likely to keep pursuing.

4. What differs clinically

Hypochondroplasia is often called a milder achondroplasia. That is accurate about stature and incomplete about management.

Findings that discriminate between the two conditions — not a complete phenotype description. Shared features such as relative macrocephaly and lumbar lordosis are omitted because they do not aid the distinction

The overlap extends downward. The skeletal features resemble achondroplasia but tend to be milder [1]. Children usually present to pediatricians or pediatric endocrinologists as toddlers or at early school age with decreased growth velocity, and limb-to-trunk disproportion is often mild and easily overlooked in infancy. At the mild end the phenotype may overlap with idiopathic or familial short stature, making a definitive clinical diagnosis difficult [1].

Craniofacial features are a useful discriminator. They are usually normal in hypochondroplasia, and the classic achondroplasia features — midface retrusion, frontal bossing — are not generally seen. The hands are relatively short but do not typically show the trident configuration [1].

Skeletal complications common in achondroplasia occur less often: foramen magnum stenosis, spinal stenosis, tibial bowing and obstructive apnea are all less frequent, spinal stenosis symptoms in adults are milder, and motor milestones are usually not significantly delayed [1].

The neurologic profile is where priorities invert. Epilepsy can present at various ages and typically has a temporal lobe focus; in infants the presentation may be subtle — apneas, cyanosis, eye deviation, vacant stares — and EEG findings can be difficult to capture [1]. Temporal lobe dysgenesis has been reported in FGFR3-related conditions, including incomplete hippocampal folding and dilatation of the temporal horns [1].

On neurocognitive outcome the evidence deserves care rather than a single number. GeneReviews notes that although intellectual disability is thought to be more common in hypochondroplasia, robust data are scarce and the observation has been controversial [1]. Among 13 Finnish individuals with confirmed p.Asn540Lys, eight had neurocognitive difficulties — specific learning disorder (2/13), mild intellectual disability (5/13), global developmental delay (1/13) [4]; a cohort of 20 molecularly confirmed Korean patients reported developmental delay in 25% [5].

The point is not that one condition is worse. It is that a patient carried as “mild achondroplasia” is monitored against a checklist weighted toward complications they are less likely to develop — and away from temporal lobe epilepsy, which may present as apnea in infancy.

5. The wider FGFR3 allelic series

Note that c.1948A>G produces thanatophoric dysplasia or SADDAN depending on the substituted residue, and that the p.Lys650 codon also appears among hypochondroplasia variants [1]. The same codon spans a lethal condition and one of the mildest in the series — this is not a gene where position-based intuition substitutes for sequencing.

6. When it is not FGFR3 at all

The differential for hypochondroplasia is not the differential for achondroplasia — a distinction often conflated. Conditions with a known genetic etiology that may be confused with hypochondroplasia include [1]:

Also to consider: short stature from disturbances of the growth hormone axis, and constitutional short stature [1]. Where the presentation is more achondroplasia-like, pseudoachondroplasia (COMP ) and spondyloepiphyseal dysplasia congenita (COL2A1) enter the differential instead.

Nomenclature has followed the molecular logic. In the 2023 revision of the Nosology of Genetic Skeletal Disorders the condition is designated FGFR3-related hypochondroplasia; patients with overlapping clinical features but a different genetic etiology are assigned to other groups entirely [1]. The molecular result does not confirm the clinical label — it determines which label applies.

7. Why the distinction is becoming therapeutically consequential

Until recently, precise subtyping changed surveillance but not therapy. That is changing.

For achondroplasia itself, consensus guidelines on implementing and monitoring vosoritide were published in 2025 [8]. Growth hormone therapy in hypochondroplasia, by contrast, has produced mixed results across small cohorts and remains experimental — with genetic heterogeneity proposed as one reason responses varied [1].

The implication is concrete: eligibility for these trials, and in time for approved therapy, is defined molecularly rather than radiographically. A patient carried as “probable achondroplasia, hotspot-negative” is a patient whose access is undetermined.

8. What the guidance supports

The International Consensus Statement on achondroplasia notes that genetic testing helps distinguish achondroplasia from hypochondroplasia and other skeletal dysplasias, and that skeletal dysplasia gene panels or whole exome sequencing can be used in patients with atypical clinical and/or radiographic presentations [7]. GeneReviews sets out the same division for hypochondroplasia: gene-targeted testing where the phenotype and radiographs suggest the diagnosis, and comprehensive genomic testing — most commonly exome sequencing — where the phenotype is indistinguishable from many other skeletal dysplasias [1].

Exome sequencing is not the end of the sequence. Where the phenotype remains convincing and coding analysis is uninformative, genome sequencing covers the deep intronic and regulatory regions inaccessible to exome capture — a case report describes clinical and radiographic achondroplasia resolved only by extending FGFR3 analysis into non-coding sequence [9]. Reanalysis as databases evolve is worthwhile in unsolved cases, and DNA banking is recommended where no molecular diagnosis has been established [1].

Frequently asked questions

Does a negative FGFR3 c.1138 test exclude achondroplasia? For practical purposes it makes classic achondroplasia very unlikely, since more than 99% of patients carry a variant at that position [9]. It does not exclude hypochondroplasia, another FGFR3-related dysplasia, or a non-FGFR3 skeletal dysplasia. If the phenotype was convincing enough to prompt testing, a negative hotspot result is a reason to broaden rather than to stop.

If I add the c.1620 hotspot, is that enough? Testing both pairs is what guidance recommends, precisely because the two presentations are easily confused [1]. It is not complete: targeted analysis of the c.1620 pair identifies roughly 70–80% of hypochondroplasia, full FGFR3 sequencing 70–90%, and in 10–30% of patients no FGFR3 variant is identified [1].

If both parents are of average stature, what is the recurrence risk? Most hypochondroplasia arises from a de novo variant, and a paternal age effect has been described in simplex cases. Where the variant is not detectable in either parent, recurrence risk to siblings is estimated at approximately 1%, reflecting the possibility of parental gonadal mosaicism [1].

Order 3B-EXOME

When the hotspot is negative: 3B-EXOME

Whole exome sequencing with variant interpretation across the full skeletal dysplasia gene set, for patients whose presentation does not fit a single-gene assay.

Order 3B-EXOME

References

  1. Bober MB, Bellus GA, Cheung MS, Jain M, Nikkel SM, Tiller GE. Hypochondroplasia. In: Adam MP, Bick S, Mirzaa GM, et al, eds. GeneReviews. Seattle, WA: University of Washington, Seattle; 1993-2026. Updated September 25, 2025. Accessed July 27, 2026. https://www.ncbi.nlm.nih.gov/books/NBK1477/
  2. Xie H, Chen Y, Xiong F, Li J, Yang F. Failure to diagnose hypochondroplasia by prenatal diagnosis: a case report. BMC Pediatr. 2023;23(1):100. doi:10.1186/s12887-023-03917-2
  3. Sabir AH, Sheikh J, Singh A, et al. Earlier detection of hypochondroplasia: a large single-center UK case series and systematic review. Am J Med Genet A. 2021;185(1):73-82. doi:10.1002/ajmg.a.61912
  4. Linnankivi T, Mäkitie O, Valanne L, Toiviainen-Salo S. Neuroimaging and neurological findings in patients with hypochondroplasia and FGFR3 N540K mutation. Am J Med Genet A. 2012;158A:3119-3125. PMID:23165795
  5. Kim HY, Lee YA, Shin CH, Cho TJ, Ko JM. Clinical manifestations and outcomes of 20 Korean hypochondroplasia patients with the FGFR3 N540K variant. Exp Clin Endocrinol Diabetes. 2023;131:123-131. PMID:36442838
  6. Dauber A, Zhang A, Kanakatti Shankar R, et al. Vosoritide treatment for children with hypochondroplasia: a phase 2 trial. EClinicalMedicine. 2024;71:102591. PMID:38813446
  7. Savarirayan R, Ireland P, Irving M, et al. International consensus statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia. Nat Rev Endocrinol. 2022;18(3):173-189. doi:10.1038/s41574-021-00595-x
  8. Savarirayan R, Hoover-Fong J, Ozono K, et al. International consensus guidelines on the implementation and monitoring of vosoritide therapy in individuals with achondroplasia. Nat Rev Endocrinol. 2025;21(5):314-324. doi:10.1038/s41574-024-01074-9
  9. Ouedraogo ZG, Janel C, Janin A, et al. Relevance of extending FGFR3 gene analysis in osteochondrodysplasia to non-coding sequences: a case report. Genes (Basel). 2024;15(2):225. doi:10.3390/genes15020225

Get exclusive rare disease updates
from 3billion.

Sookjin Lee

Expert in integrating cutting-edge genomic healthcare technologies with market needs. With 15+ years of experience, driving impactful changes in global healthcare.

Read More from This Author

Recommended For You